ESCRS 2024 Grandly Held ：Eyedeal xPIB Innovations Draw Global Ophthalmology Industry Attention

From September 6th to 10th, the highly anticipated 42nd Annual Congress of the European Society of Cataract and Refractive Surgeons (ESCRS 2024) was grandly held in Barcelona, Spain. Tens of thousands of ophthalmology experts, scholars, and industry professionals from around the world gathered to share research achievements and exchange insights on industry developments. The innovative accomplishments of  Eyedeal’s xPIB attracted widespread attention, demonstrating the company’s commitment to participating in international scientific innovation and collaborative exchanges with an even more open attitude.

During the conference, the Eyedeal booth attracted a continuous stream of international ophthalmic experts. Upon learning about the company’s independently developed, next-generation cross-linked polyisobutylene (xPIB) intraocular lens (IOL), many experts picked up magnifying glasses to closely examine the product’s mechanical and optical design, and even touched the lens themselves to feel its mechanical properties. The superior material performance of xPIB drew widespread admiration from those on site.

When informed that the xPIB IOL can achieve an ultra-large 8mm optical zone, Dr. Guy Kleinmann, an ophthalmic expert from Israel, remarked, “Eyedeal’s innovative breakthrough marks a significant transformation in the field of ophthalmic materials. We are eager to see its application in clinical practice.”

Many professional doctors from renowned hospitals and clinical research institutions around the world also expressed high expectations for the future application of the xPIB IOL. Several stated their willingness to participate in international clinical collaborative research on the material, aiming to jointly promote the global application of this innovative intraocular lens. Dr. Fritz H. Hengerer, a senior ophthalmologist from Germany, commented, “In the past 30 years, I have never seen such an innovative material. This will bring many new possibilities to ophthalmic surgery.”

During the conference, representatives from leading international medical companies from the UK, Germany, the United States, and other countries also explored with  Eyedeal the potential applications and development prospects of xPIB in other medical fields. Experts agreed that xPIB has not only achieved a breakthrough in ophthalmology but also holds extraordinary potential and value across the broader healthcare industry.

Guangxu Guo, Chairman and CEO of Eyedeal, stated that as a participant in the global pharmaceutical industry, the company will continue to focus on medical raw materials and innovative medical devices. Eyedeal is committed to fostering open collaboration with global medical experts to drive technological progress and contribute to the advancement of global eye health.